Hazlehurst LA - Search Results

1

Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.

Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS. Hazlehurst LA, et al. Cancer Res. 2003 Nov 15;63(22):7900-6. Cancer Res. 2003. PMID: 14633719

2

Chromosome mediated gene transfer of drug resistance to mitoxantrone.

Hazlehurst LA, Gros P, Dalton WS. Hazlehurst LA, et al. Anticancer Res. 1998 Mar-Apr;18(2A):1005-10. Anticancer Res. 1998. PMID: 9615755

3

Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.

Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Damiano JS, et al. Among authors: hazlehurst la. Blood. 1999 Mar 1;93(5):1658-67. Blood. 1999. PMID: 10029595 Free PMC article.

4

Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line.

Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW, De Jong MC, Dalton WS. Hazlehurst LA, et al. Cancer Res. 1999 Mar 1;59(5):1021-8. Cancer Res. 1999. PMID: 10070958

5

Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).

Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Hazlehurst LA, et al. Oncogene. 2000 Sep 7;19(38):4319-27. doi: 10.1038/sj.onc.1203782. Oncogene. 2000. PMID: 10980607

6

Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation.

Damiano JS, Hazlehurst LA, Dalton WS. Damiano JS, et al. Among authors: hazlehurst la. Leukemia. 2001 Aug;15(8):1232-9. doi: 10.1038/sj.leu.2402179. Leukemia. 2001. PMID: 11480565

7

Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.

Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS. Hazlehurst LA, et al. Blood. 2001 Sep 15;98(6):1897-903. doi: 10.1182/blood.v98.6.1897. Blood. 2001. PMID: 11535527 Free article.

8

Multiple Myeloma: New Insights and Therapeutic Approaches.

Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J. Anderson KC, et al. Hematology Am Soc Hematol Educ Program. 2000:147-165. doi: 10.1182/asheducation-2000.1.147. Hematology Am Soc Hematol Educ Program. 2000. PMID: 11701540

9

Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells.

Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R, Dalton WS. Oshiro MM, et al. Among authors: hazlehurst la. Clin Cancer Res. 2001 Dec;7(12):4262-71. Clin Cancer Res. 2001. PMID: 11751528

10

Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies.

Hazlehurst LA, Dalton WS. Hazlehurst LA, et al. Cancer Metastasis Rev. 2001;20(1-2):43-50. doi: 10.1023/a:1013156407224. Cancer Metastasis Rev. 2001. PMID: 11831646 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

74 results

Search Page

Filters